ArticleFolia microbiologica2025
Flurbiprofen restores rifampicin and isoniazid sensitivity in multidrug-resistant Mycobacterium tuberculosis putatively by inhibiting efflux pumps Rv0194 and Rv0933.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
asbtractMultidrug-resistant tuberculosis remains a global health challenge, necessitating novel therapeutic approaches. Efflux pumps, including Rv0194 and Rv0933, contribute to Mycobacterium tuberculosis resistance by actively extruding first-line drugs such as rifampicin and isoniazid. This study aimed to identify small-molecule inhibitors that target these pumps to restore drug susceptibility. Through in silico screening, six lead compounds were selected and evaluated for antimicrobial activity against ten MDR-TB clinical isolates. Among them, flurbiprofen and trichlorocarbinalide exhibited significant inhibitory effects, enhancing rifampicin and isoniazid activity in checkerboard synergy assays. These combinations reduced the minimum inhibitory concentrations of both drugs, confirming their potential to reverse resistance. Cytotoxicity assessments of peripheral blood mononuclear and THP-1 cells demonstrated favourable safety profiles. Mechanistic studies revealed increased expression of Rv0194 and Rv0933 upon rifampicin and isoniazid exposure, underscoring their role in drug resistance. Flurbiprofen and trichlorocarbinalide may enhance intracellular drug retention by inhibiting these efflux pumps, improving therapeutic efficacy. However, trichlorocarbinalide did not restore rifampicin or isoniazid sensitivity as efficiently as flurbiprofen did. These findings highlight flurbiprofen as a promising efflux pump inhibitor that could potentiate standard TB treatments and counteract resistance. Further studies using diverse clinical isolates and in vivo models are needed to validate its therapeutic potential.
Indexed as
Identifiers
40976821What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.